Literature DB >> 15790790

Distinct hematopoietic progenitor compartments are delineated by the expression of aldehyde dehydrogenase and CD34.

Robert W Storms1, Patrick D Green, Kristine M Safford, Donna Niedzwiecki, Christopher R Cogle, O Michael Colvin, Nelson J Chao, Henry E Rice, Clayton A Smith.   

Abstract

A broad range of hematopoietic stem cells and progenitors reside within a fraction of umbilical cord blood (UCB) that exhibits low light scatter properties (SSC(lo)) and high expression of aldehyde dehydrogenase (ALDH(br)). Many SSC(lo) ALDH(br) cells coexpress CD34; however, other cells express either ALDH or CD34. To investigate the developmental potential of these cell subsets, purified ALDH(br) CD34+, ALDH(neg) CD34+, and ALDH(br) CD34(neg) UCB cells were characterized within a variety of in vivo and in vitro assays. Primitive progenitors capable of multilineage development were monitored in long- and short-term repopulation assays performed on nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice, and in primary and secondary long-term culture assays. These progenitors were highly enriched within the ALDH(br) CD34+ fraction. This cell fraction also enriched short-term myeloid progenitors that were detected in vitro. By comparison, ALDH(neg) CD34+ cells contained few primitive progenitors and had diminished short-term myeloid potential but exhibited enhanced short-term natural killer (NK) cell development in vitro. The ALDH(br) CD34(neg) cells were not efficiently supported by any of the assays used. These studies suggested that in particular the expression of ALDH delineated distinct CD34+ stem cell and progenitor compartments. The differential expression of ALDH may provide a means to explore normal and malignant processes associated with myeloid and lymphoid development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790790      PMCID: PMC1895136          DOI: 10.1182/blood-2004-09-3652

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages.

Authors:  K Akashi; D Traver; T Miyamoto; I L Weissman
Journal:  Nature       Date:  2000-03-09       Impact factor: 49.962

2.  Identification of a novel, human multilymphoid progenitor in cord blood.

Authors:  Q L Hao; J Zhu; M A Price; K J Payne; L W Barsky; G M Crooks
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

3.  SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intra-bone marrow injection.

Authors:  Jianfeng Wang; Takafumi Kimura; Rumiko Asada; Sachio Harada; Shouhei Yokota; Yoshio Kawamoto; Yoshihiro Fujimura; Takashi Tsuji; Susumu Ikehara; Yoshiaki Sonoda
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

4.  Human CD34+ cell preparations contain over 100-fold greater NOD/SCID mouse engrafting capacity than do CD34- cell preparations.

Authors:  Z Gao; M J Fackler; W Leung; R Lumkul; M Ramirez; N Theobald; H L Malech; C I Civin
Journal:  Exp Hematol       Date:  2001-07       Impact factor: 3.084

Review 5.  In search of "stemness".

Authors:  Jingli Cai; Mark L Weiss; Mahendra S Rao
Journal:  Exp Hematol       Date:  2004-07       Impact factor: 3.084

6.  Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity.

Authors:  David A Hess; Todd E Meyerrose; Louisa Wirthlin; Timothy P Craft; Phillip E Herrbrich; Michael H Creer; Jan A Nolta
Journal:  Blood       Date:  2004-06-03       Impact factor: 22.113

7.  Reversible expression of CD34 by adult human bone marrow long-term engrafting hematopoietic stem cells.

Authors:  Esmail D Zanjani; Graça Almeida-Porada; Anne G Livingston; HaiQun Zeng; Makio Ogawa
Journal:  Exp Hematol       Date:  2003-05       Impact factor: 3.084

8.  Mobilized peripheral blood SSCloALDHbr cells have the phenotypic and functional properties of primitive haematopoietic cells and their number correlates with engraftment following autologous transplantation.

Authors:  Paul Fallon; Tracy Gentry; Andrew E Balber; David Boulware; William E Janssen; Renee Smilee; Robert W Storms; Clay Smith
Journal:  Br J Haematol       Date:  2003-07       Impact factor: 6.998

9.  Expression of CD33, CD38, and HLA-DR on CD34+ human fetal liver progenitors with a high proliferative potential.

Authors:  M O Muench; J Cupp; J Polakoff; M G Roncarolo
Journal:  Blood       Date:  1994-06-01       Impact factor: 22.113

10.  Reversibility of CD34 expression on human hematopoietic stem cells that retain the capacity for secondary reconstitution.

Authors:  Mo A Dao; Jesusa Arevalo; Jan A Nolta
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

View more
  41 in total

1.  The enzymatic activity of human aldehyde dehydrogenases 1A2 and 2 (ALDH1A2 and ALDH2) is detected by Aldefluor, inhibited by diethylaminobenzaldehyde and has significant effects on cell proliferation and drug resistance.

Authors:  Jan S Moreb; Deniz Ucar; Shuhong Han; John K Amory; Alex S Goldstein; Blanca Ostmark; Lung-Ji Chang
Journal:  Chem Biol Interact       Date:  2011-11-03       Impact factor: 5.192

Review 2.  The role of human aldehyde dehydrogenase in normal and cancer stem cells.

Authors:  Irene Ma; Alison L Allan
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

3.  Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.

Authors:  Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich
Journal:  Cancer Res       Date:  2011-04-15       Impact factor: 12.701

Review 4.  Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

Authors:  D L DiGiusto; L J N Cooper
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

5.  An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

Authors:  Georg Feldmann; Volker Fendrich; Karen McGovern; Djahida Bedja; Savita Bisht; Hector Alvarez; Jan-Bart M Koorstra; Nils Habbe; Collins Karikari; Michael Mullendore; Kathleen L Gabrielson; Rajni Sharma; William Matsui; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

6.  Aldehyde dehydrogenase activity identifies a population of human skeletal muscle cells with high myogenic capacities.

Authors:  Karine Vauchez; Jean-Pierre Marolleau; Michel Schmid; Patricia Khattar; Alain Chapel; Cyril Catelain; Séverine Lecourt; Jérôme Larghéro; Marc Fiszman; Jean-Thomas Vilquin
Journal:  Mol Ther       Date:  2009-09-08       Impact factor: 11.454

7.  Targeting aldehyde dehydrogenase: a potential approach for cell labeling.

Authors:  Ganesan Vaidyanathan; Haijing Song; Donna Affleck; Darryl L McDougald; Robert W Storms; Michael R Zalutsky; Bennett B Chin
Journal:  Nucl Med Biol       Date:  2009-10-03       Impact factor: 2.408

8.  Epigenetic reprogramming induces the expansion of cord blood stem cells.

Authors:  Pratima Chaurasia; David C Gajzer; Christoph Schaniel; Sunita D'Souza; Ronald Hoffman
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

9.  Aldehyde dehydrogenase activity as a functional marker for lung cancer.

Authors:  Deniz Ucar; Christopher R Cogle; James R Zucali; Blanca Ostmark; Edward W Scott; Robert Zori; Brian A Gray; Jan S Moreb
Journal:  Chem Biol Interact       Date:  2008-10-05       Impact factor: 5.192

10.  Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity.

Authors:  Garrett G Muramoto; J Lauren Russell; Rachid Safi; Alice B Salter; Heather A Himburg; Pamela Daher; Sarah K Meadows; Phuong Doan; Robert W Storms; Nelson J Chao; Donald P McDonnell; John P Chute
Journal:  Stem Cells       Date:  2010-03-31       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.